Kornimate/medical-research-clean huggingface dataset:
the relationship between idiopathic acute peripheral facial paralysis and homocysteine level in adult patients

Conditions: Facial Paralysis, Peripheral; Bell Palsy

Summary: in the etıology of idıopathıc acute perıpheral facıal palsy, known as bell palsy, many causes have been descrıbed, such as specıfıc ımmune, ıchemıc, ınfectıous and heredıal factors. ın our study, we have observed the blood homocysteıne level that causes thrombotıc dısorders ın paralysıs patıents.

bell's palsy, also known as "acute facial palsy of unknown cause", is a common cranial neuropathy that characteristically causes facial muscle paresis or complete paralysis on one side, occurs suddenly and may progress over 48 hours. it is accompanied by postauricular pain, dysgeusia, subjective alteration of facial sensation, and hyperacusis. bell's palsy accounts for 60-75 percent of all cases of facial palsy. it occurs in 7-40 cases per 100,000 people each year, and the prevalence is similar in both sexes. its cause remains idiopathic, but it is strongly associated with certain viral infections, which cause neuritis leading to focal edema, demyelination, and ischemia. although the exact pathogenesis of bell's palsy is unknown and is considered idiopathic, specific immune, ischemic, and hereditary factors are strongly associated with its etiology. homocysteine is an amino acid that is not provided by the diet and can be converted to cysteine with the help of specific b vitamins or converted back to methionine, an essential amino acid. homocysteine levels vary between men and women and are usually in the normal range of 5 to 15 micromoles/l. when homocysteine levels exceed 15 micromoles/l, it is called hyperhomocysteinemia. the estimated prevalence of mild hyperhomocysteinemia in the general population is 5% to 7%. several studies have shown that it is an independent risk factor for thrombotic disorders (i.e., deep vein thrombosis). it has even been reported that lowering a patient's homocysteine level by 25% reduces the risk of stroke by 19%. a significant relationship was found in the meta-analysis conducted in the literature regarding sudden sensorineural hearing loss and high homocysteine levels. due to the similar anatomical location of the facial nerve and n. vestibulocochlearis, it was planned to examine the relationship between acute idiopathic peripheral paralysis and homocysteine. there is no previous study in the literature. therefore, this study will be the pioneering research in the literature regarding blood homocysteine levels in patients diagnosed with idiopathic acute peripheral facial paralysis.

Eligibility criteria:
inclusion criteria: - patients admitted with acute facial paralysis exclusion criteria: * facial and ear trauma or tumor * i̇atrogenic * cholesteatoma * facial paralysis due to central nervous system diseases

Keywords: acute peripheral facial paralysis homocysteine bell palsy
comparison of ex-presstm mini glaucoma shunt to trabeculectomy in subjects with open angle glaucoma

Conditions: Glaucoma

Summary: a prospective randomized trial to compare the safety and efficacy of the ex-press to trabeculectomy in patients with open angle glaucoma who failed medical or are allergic to medical treatment and for which filtering surgery is indicated. surgical success was defined as 5 mmhg ≤ intraocular pressure ≤ 18 mmhg, with or without medications, without further glaucoma surgery. postoperative intraocular pressure, number of medications, complications and success rates were followed for 2 years.


Eligibility criteria:
inclusion criteria: * adult subject over the age of 18 * subject diagnosed with open angle glaucoma (poag, pxfg or pdsg) or ocular hypertension * subject is a candidate for filtering surgery with intraoperative anti-metabolites * iop \> 18 mmhg on maximum tolerated medial therapy based on two measurements taken 1 hour apart at the same visit. * subject willing to attend all follow-up evaluations * subject willing to sign informed consent. exclusion criteria: * subject diagnosed with: pacg, ntg, secondary glaucoma, neovascular glaucoma * subject has history of glaucoma surgery (filtering, glaucoma drainage device, cyclo destructive procedures) * subject has history of penetrating keratoplasty (pkp) * subject underwent large incision extra capsular cataract extraction * subject had cataract phacoemulsification within the last month * subject has a visually significant cataract that is planned for extraction at the time of filtering surgery or within 12 months thereafter * any ocular disease or history in the operated eye other than glaucoma and cataract, such as uveitis, ocular infection, severe dry eye, severe blepharitis , active proliferative retinopathy, ice syndrome, epithelial or fibrous down growth, aphakia, and ocular pathology that may interfere with accurate iop measurements * subject has vitreous present in the anterior chamber for which vitrectomy is anticipated * iop of ≤18mmhg * subject participates in any other concurrent ocular investigation.

Keywords: ex-press trabeculectomy
european multicentric study on parathyroid carcinoma

Conditions: Parathyroid Carcinoma

Summary: the main aim of the study is to evaluate the incidence of post-operative diagnosis of pc and atypical parathyroid neoplasm in patients who underwent surgery for phpt in different european centers using the eurocrine® database. moreover, we aim to evaluate the peri-operative surgical characteristics, operation extent, postoperative morbidity, and outcomes in these patients category.

parathyroid cancer (pc) is one of the rarest malignancies (0.005% of all tumours) and it represents less than 1% of all the causes of primary hyperparathyroidism (phpt). it is frequently a sporadic disease, but it can be part of hereditary syndromes (i.e. hpt- jt, men, men2a and fihp). clinical and biochemical presentation is usually more severe comparing to other forms of primary hyperparathyroidism as it is often associated to very high serum-calcium and pth levels and target organs' damages. malignancy should be suspected on the basis of the aforementioned biochemical data and the imaging evidences (such as parathyroid lesion dimension \>3 cm, faded edges, inhomogeneous internal features and cervical lymph nodes enlargement). in case of suspected pc a radical treatment should be proposed to the patient, consisting of parathyroidectomy and en bloc ipsilateral hemithyroidectomy and ipsilateral central neck dissection. indeed, the oncological radicality during surgical treatment is mandatory, as effective adjuvant therapy is not available. however, pre-operative differential diagnosis with parathyroid adenoma is still challenging, thus malignancy can be detected only after the histological analysis of the specimen and sometimes after recurrences. moreover, parathyroid atypical adenoma entity is still controversial, as it presents suspicious histological features, but certain signs of malignancy are lacking (such as capsular, vessels and neural invasion). furthermore, natural history and biological behaviour are still unknown.

Eligibility criteria:
inclusion criteria: all adult (18 years old and older) patients that underwent surgery for primary hyperparathyroidism with a final histology of parathyroid carcinoma from 2015 till 2021. inclusion criteria: * all adult (18 years old and older) patients * underwent surgery * final histology of parathyroid carcinoma * among european centers that participate in the eurocrine® database between 2015 and 2021 exclusion criteria: • patients \<18 years old

Keywords: parathyroid carcinoma primary hyperparathyroidism eurocrine
trigger thumb randomized controlled trial

Conditions: Trigger Thumb

Summary: we are conducting this study to determine if administration of local anesthetic to the thumb prior to surgery can reduce the amount of anesthetic gas given during the course of surgery.


Eligibility criteria:
inclusion criteria: 1. males or females, age 0-4 years, presenting to the children's hospital of philadelphia (chop) department of orthopaedics with unilateral trigger thumb that requires surgical treatment. 2. american society of anaesthesiologists (asa) classification of 1 or 2. 3. parental/guardian permission (informed consent). exclusion criteria: 1. males or females over the age of 4. 2. asa classification higher than 2. 3. patients presenting with systemic diseases or significant comorbidities. 4. patients that received treatment for trigger thumb at an outside institution.
fully coated, removable, self-expanding oesophageal stents for preventing strictures following complete barretts excision.

Conditions: Constriction, Pathological

Summary: the purpose of this study is to investigate whether preventative placement of a removable oesophageal stent reduces the rate of scar tissue, or stricture formation after removing the precancerous or early cancerous barrett's mucosa by endoscopic mucosal resection (emr). the stent will be placed 10-14 days after initial emr. the stent will then be removed 8 weeks later by repeat endoscopy. patients will be followed up weekly following insertion of the oesophageal stent.


Eligibility criteria:
inclusion criteria: * patients with short segment barrett's oesophagus with high grade dysplasia or early cancer, having circumferential emr to achieve complete barrett's excision. * aged 18-75 years old * biopsy proven to be barretts with hgd or eac * the absence or lymph node involvement * short segment \<3cm of barretts oesophagus. exclusion criteria: * women who are pregnant and the human foetus * children and/or young people \<18 years * people with an intellectual or mental impairment.

Keywords: stricture dysphagia
cognitive-behavioral therapy for pain and opioid dependence in methadone maintenance treatment

Conditions: Chronic Pain; Opiate Dependence

Summary: this study involves the comparison of two treatment approaches for patients with chronic pain who are entering methadone maintenance treatment (mmt) for opioid addiction: (a) an integrated counseling that addresses both chronic pain and opioid dependence(pod)and (b) a counseling intervention that addresses opioid dependence only.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * prescription opioid or heroin addiction * moderate to severe chronic pain * enrolled in methadone maintenance at the apt foundation for opioid addiction * understand english exclusion criteria: * current suicide or homicide risk * life-threatening or unstable medical problem
kidney therapy for free light chain removal in patients with multiple myeloma & cast nephropathy

Conditions: Multiple Myeloma; Cast Nephropathy; Acute Kidney Injury

Summary: hypothesis: free light chain (flc) removal haemodialysis will increase the rate of renal recovery in patients with cast nephropathy, severe renal failure and de novo multiple myeloma. this study will evaluate patients with multiple myeloma and severe renal failure treated with kidney therapy (previously called supra hfr) to remove free light chains.

this is an observational study performed to investigate the clinical benefit of flc removal by kidney therapy system in patients with cast nephropathy, dialysis dependent renal failure and de novo multiple myeloma. recruitment commenced in july 2014, in total 20 patients will be recruited. participants will be treated with, kidney therapy system (bellco mirandola, modena, italy) . the kidney system is a kind of haemodiafiltration that utilizes separated convection, diffusion and adsorption. the sorbent cartridge has a high affinity for flc (both κ and λ) but is able to re-infuse albumin, avoiding the need for albumin perfusions. the kidney therapy will be undertaken over an intensive treatment schedule. the primary outcome for the study is independence of dialysis in 3 month. secondary outcomes are: duration dialysis, reduction of serum flc levels, myeloma response and survival.

Eligibility criteria:
inclusion criteria: * age \>= 18 years * dialysis dependent acute renal failure * fulfils diagnostic criteria for the diagnosis of symptomatic de novo multiple myeloma * abnormal serum flc ratio and a sflc concentration \> 500 mg/l * myeloma kidney demonstrated on a renal biopsy (cast nephropathy) * ability to give informed consent to partake in study * commencement of study within 10 days of presenting to enrolling unit exclusion criteria: * known advanced chronic renal failure (ckd stage iv 4-5; egfr \<30mls/min/1.73m2) or evidence of significant chronic damage on renal biopsy * amyloidosis or light chain deposition disease on renal biopsy * previous treatment of multiple myeloma with chemotherapy * haemodynamic instability that precludes unsupported dialysis renal replacement therapy * significant cardiac disease * active uncontrolled infection * inability to give informed consent

Keywords: multiple myeloma cast nephropathy acute kidney injury kidney therapy hfr
a pilot study of total-body pet using fda-approved radiotracers beyond 18f-fdg

Conditions: Prostate Cancer; Breast Cancer; Neuroendocrine Tumors

Summary: the purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (pet)/computed tomography (ct) scanner (explorer) by collecting data from pet scans using one of three different imaging agents: 18f-psma; 18f-fes; or, 68ga dotatate. these imaging agents are approved by the fda to be used for patients diagnosed with prostate cancer (18f-psma), neuroendocrine tumor (68ga dotatate), or breast cancer (18f-fes).


Eligibility criteria:
18f-psma (n=3) and 68ga-psma (n=3) inclusion criteria: * persons \>18 yo with suspected prostate cancer metastasis * prior imaging study (ct, and/or mri and/or bone scan and/or fluciclovine scan) suspicious for metastatic disease, obtained within 4 months from the research scan date. 68ga dotatate (n=3) or 64cu-dotatate (n=3) inclusion criteria: * persons \> 18 yo suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors (nets) * prior dotatate pet/ct scan suspicious for tumor obtained not earlier than 4 months from the research scan date. exclusion criteria: • recent administration of long-acting somatostatin analogs exclusion criteria for all participants: * adults unable to consent * pregnant/lactating persons * prisoners * unable to lie supine for up to 90 minutes at different timepoints in the pet scanner * uncontrolled claustrophobia * any significant medical condition that in the opinion of the investigator would prevent the participant from participating and/or adhering to study related procedures or interfere with participant safety
genetic polymorphism and post operative nausea and vomiting (ponv)

Conditions: Genetic Predisposition to Disease; Postoperative Nausea; Polymorphism, Genetic

Summary: nausea and vomiting affects 25-30% of individuals in the post-operative period and can reach more than 70-80% in high-risk patients. inherited factors may play a significant role in individual susceptibility and clinical research on hereditary factors involved in the pathogenesis of postoperative nausea and vomiting (ponv) and chemotherapy nausea and vomiting (cinv) is relatively new. the aim of this study is to investigate whether inter-individual differences related to ponv are associated with genetic factors. 300 patients will be evaluated in postoperative oncological surgeries. the peripheral leukocyte dna will be extracted by the salting out procedure method and processed to genotyping for 48 snps from 15 candidate genes by real-time pcr by the taqman method. the possible associations with demographic data and factors related to surgery will be analyzed by univariate and multivariate analysis.

the aim of this study is to investigate whether inter-individual differences related to ponv are associated with genetic factors. 300 patients will be evaluated in postoperative oncological surgeries. the peripheral leukocyte dna will be extracted by the salting out procedure method and processed to genotyping for 48 single nucleotide polymorphisms (snps) from 15 candidate genes by real-time pcr by the taqman method. the possible associations with demographic data and factors related to surgery will be analyzed by univariate and multivariate analysis.

Eligibility criteria:
inclusion criteria: * high and intermediate-risk patients for ponv (apfel score 2, 3 and 4) exclusion criteria: * low risk patients for ponv (apfel score 0 and 1)
a study to evaluate safety, and efficacy of suvn-g3031 (samelisant) in patients with narcolepsy with and without cataplexy

Conditions: Narcolepsy

Summary: this study is of an investigational drug called suvn-g3031 (samelisant) as a possible treatment for narcolepsy with cataplexy or narcolepsy without cataplexy. the main purpose of this study is to learn how well the study drug works and how safe the study drug is compared to placebo.

this is a phase 2, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics (pk), and efficacy of suvn-g3031 compared to placebo in participants with narcolepsy with and without cataplexy. participants will be randomized at a ratio of 1:1:1 to 2 mg suvn-g3031, 4 mg suvn-g3031, or placebo. each participant will receive study drug once daily, in a tablet formulation, for 14 days.

Eligibility criteria:
inclusion criteria: * ages of 18 to 65 years (adult), inclusive. * have narcolepsy with or without cataplexy (na-1 or na-2) based on the international classification of sleep disorders (3rd edition) criteria (new or previously diagnosed). * have undergone a multiple sleep latency test (mslt) study showing an mslt of ≤ 8 minutes. * an epworth sleepiness scale (ess) score of ≥ 12; and mean maintenance of wakefulness test (mwt) time of \< 12 min. * body mass index ranging from 18 to \< 45 kg/m2 * negative urine drug screen. * a woman must be either not of childbearing potential or of childbearing potential practicing highly effective methods of birth control. * willingness to complete the study protocol with full compliance with procedures and sign an informed consent form (icf). exclusion criteria: * habitual wake-up time after 8 am as assessed by sleep diary, habitual sleep time of \< 6 hours, and habitual bedtime past 1 am as determined by sleep diary entries. * use of any investigational therapy within the 30-day period prior to enrollment. * excessive caffeine (defined as \> 600 mg/per day) use at least 1 week prior to baseline assessments and during the course of the trial. * nicotine dependence that has an effect on sleep (eg, a patient who routinely awakens at night to smoke). * use of concurrent medications prescribed to treat narcolepsy as specified including stimulants, antidepressants and sodium oxybate. * current diagnosis of or past treatment for syndromes known to cause sleep disruption or any other cause of daytime sleepiness. * clinically significant ecg abnormalities. * an occupation requiring variable shift work, night shifts, or frequent overnight travel which disrupts sleep patterns.

Keywords: suvn-g3031 narcolepsy with and without cataplexy cataplexy narcolepsy type 1 narcolepsy type 2 excessive daytime sleepiness (eds) histamine h3 receptor samelisant
bovine colostrum in prevention of sepsis and retinopathy of prematurity

Conditions: Preterm

Summary: the aim of this study is to evaluate efficacy of bovine colostrum administration as a prophylaxis to decrease the incidence and the occurrence of retinopathy of prematurity in preterm neonates of gestational age less than 32 weeks during their hospital stay.

this study will include a randomized controlled trial carried out on preterm neonates who will fulfill the eligibility criteria delivered at alexandria university children's hospital. evaluation of the outcome will be done only for those who admitted to the neonatal intensive care unit (nicu) at alexandria university children's hospital. the study will be carried out in 4 phases: 1. first phase: enrollment and selection phase. 2. second phase: intervention phase ( enteral bovine colostrum administration) . 3. third phase: evaluation phase. 4. fourth phase: collected data analysis and results.

Eligibility criteria:
inclusion criteria: * preterm infants ≤ 32 weeks gestational age, weight ≤ 1500 gm. start feeding in the first 72 hours of life exclusion criteria: * exclusion criteria patients with any of the following will be excluded: 1. obvious major congenital abnormalities. 2. infants expected to be \>72 hours of age at the time of randomization. 3. parental consent lacking/refusal

Keywords: premature infants colostrum rop
development of inflammation and fibrosis index, combining mri and pet 18f-fdg, in patient's with crohn's disease

Conditions: Crohn Disease

Summary: chronic inflammatory bowel disease (ibd) is a disabling, incurable condition that affects 250,000 people in france, and crohn's disease (cd) is the most common form. cd progresses, in one-quarter of the cases, towards the appearance of intestinal stenosis, most often on the terminal ileum, sometimes with obstructive symptoms and requiring an optimization of medical treatment (biotherapies) and/or surgery the hypothesis of this study is \[18f\]fdg pet /ct, (positron emission tomography with the tracer fluorine-18 (18f) fluorodeoxyglucose (fdg), called \[18f\]fdg pet coupled to a dedicated ct scanner) could help quantify intestinal inflammation in patients with abnormal entero-mri, and differentiate inflammation and fibrosis on a joint pet /ct and mri , in patients with complicated crohn disease intestinal stenosis

intestinal inflammation could be quantified by the pet/ct due to the tropism of a pet tracer, \[18f\]fdg for activated inflammatory cells. \[18f\]fdg pet/ctperformed on latest digital pet/ct cameras and recordings focused on the abdomen could help quantify intestinal inflammation in patients with abnormal entero-mri, and differentiate inflammation and fibrosis on a joint pet/ct and mri , in patients with complicated crohn disease intestinal stenosis. magnetic resonance imaging (mri) indices are used to assess the upgradability and activity of cd and try to predict response to treatment, in particular nancy's mri score for digestive inflammation. an inflammation index (film-i) and a fibrosis index (film-f), based on this mri/pet analysis, will be developed and validated to develop personalized medicine in patients with stenosing cd. indeed, these indices will guide the therapeutic choice, in particular for the biotherapies prescription or the need to operate these patients.

Eligibility criteria:
inclusion criteria: * major subject having received complete information of the clinical research and having signed their informed consent * subject with a stenosing cd (objectified on mri, ct and / or endoscopy). * subject for which surgical resection of one or more stenosis (s) of the terminal ileum is programmed as part of the treatment. * subject with a social security scheme exclusion criteria: * subject having a contraindication to performing mri and / or pet / ct at 18f-fdg. * subject with an ostomy * diabetic subject treated by metformin. * subject referred to in articles l. 1121-5, l. 1121-7 and l1121-8 of the public health code. * pregnant woman, parturient or nursing mother. * subject with a legal protection measure (guardianship, curatorship, safeguard of justice). * subject unable to express consent. * subject deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care under articles l. 3212-1 and l.3213-1.